Skip navigation

News Summary: Perrigo to buy Elan for $8.6 billion

TIEING THE KNOT: U.S. drugmaker Perrigo agreed Monday to buy Ireland's Elan for $8.6 billion in a deal that should allow the rapidly growing company to reduce its tax bill and boost its royalty stream. Full story

Wall St. declines as investors focus on Fed policy meeting

NEW YORK (Reuters) - Stocks fell on Monday, pulling back before this week's Federal Reserve meeting that could signal when the Fed is going to begin reducing its bond purchases aimed at helping the economic recovery. Full story

Perrigo to buy Elan for $8.6B, seeks tax savings

U.S. drugmaker Perrigo agreed Monday to buy Ireland's Elan for $8.6 billion in a deal that should allow the rapidly growing company to reduce its tax bill and boost its royalty stream. Full story

Merger Monday: Three major deals on the table

   CNBC's David Faber breaks down the details on three multi-billion dollar mergers, including Omnicom & Publicis, Hudson's Bay bid for Saks, and Perrigo's acquisition of Elan.

Johnson & Johnson results beat forecasts; Elan share sale helps

(Reuters) - Johnson & Johnson <JNJ.N> on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp <ELN.I> skewed the results. Full story

Exclusive: Forest mulls bid for Irish drugmaker Elan - sources

NEW YORK (Reuters) - Forest Laboratories Inc, the specialty drugmaker that counts investor Carl Icahn as a major shareholder, is among a handful of companies interested in bidding for Irish drugmaker Elan Corp Plc, two people familiar with the situation said. Full story

Sponsored Links

Articles

Royalty drops hostile bid for Ireland's Elan

Royalty bid for Elan in trouble ahead of key meeting

Divisive Elan boss Martin faces ownership showdown

Royalty wants appeal over Elan bid heard next week

Royalty pursuing hostile bid for Elan, fights Irish panel ruling

Analysis: SAC insider-trading probe could last years

U.S. court freezes Royalty's bid for drugmaker Elan

Elan says has 'Plan B' if shareholders reject deals

Elan rejects Royalty's $6.4 billion raised offer

Elan eyes more deals this year with $1 billion warchest

Video

  Faber's Mad Dash of M&A

CNBC's David Faber has the update on potential buyers for Health Management and Royalty Pharma dropped takeover bid for Elan.

  Faber Report: Royalty Pharma Invited to Bid for Elan

CNBC's David Faber reports Elan has decided to proceed with a formal sale process in response to recent interest.

  Faber: Royalty Pharma Increases Bid for Elan

CNBC's David Faber reports the latest details on Royalty Pharma's offer to acquire Elan for $13 per share, plus continent value right based on future sales of Tysabri.

  How Tesla’s success is rewriting the future for electric cars

MSNBC's Lawrence O'Donnell explains why Tesla the electric car company’s early government loan repayment shows why Republicans are wrong to bet against President Obama.

  Justin Bieber and the state of race jokes in 2013

The Daily Show’s Lizz Winstead, the University of Pennsylvania’s Anthea Butler, and comedian Elon James White join Melissa Harris-Perry to talk about Justin Bieber’s stint on SNL and where and when it’s okay to turn race issues into comedy.

advertisement | ad info

Related Photos

Kelly Martin, President and CEO of Elan, speaks at the Reuters Health Summit in New York
Kelly Martin, President and CEO of Elan, speaks at the Reuters Health Summit in New York

File photo of Kelly Martin, CEO of Elan, speaking at the Reuters Health Summit in New York November 17, 2008. REUTERS/Brendan McDermid